Post-chemotherapy laparoscopic retroperitoneal lymph node dissection in low volume residual germ cell cancer. A technique to reduce morbidity

被引:0
|
作者
Aufderklamm, S. [1 ]
Todenhoefer, T. [1 ]
Hennenlotter, J. [1 ]
Gakis, G. [1 ]
Mischinger, J. [1 ]
Mundhenk, J. [1 ]
Germann, M. [1 ]
Stenzl, A. [1 ]
Schwentner, C. [1 ]
机构
[1] Univ Tubingen, Urol Klin, D-72076 Tubingen, Germany
来源
UROLOGE | 2013年 / 52卷 / 08期
关键词
Testicular cancer; Morbidity; operative; Space-occupying lesion; persisting; Chemotherapy; platinum-based; Resection; bilateral; TESTIS CANCER; ADJUVANT CHEMOTHERAPY; STAGE-I; TUMOR; LYMPHADENECTOMY; COMPLICATIONS; METASTASES;
D O I
10.1007/s00120-013-3133-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Retroperitoneal lymph node dissection (RPLND) is the most appropriate method for the detection of residual tumor tissue and mature teratoma after chemotherapy in patients with advanced nonseminomatous (NSGCT) or seminomatous (SGCT) germ cell tumors in clinical stage II-III. Open surgical procedures are associated with higher morbidity rates and laparoscopic RPLND offers a minimally invasive procedure with equivalent oncological safety and low morbidity. In 39 patients laparoscopic RPLND (L-RPLND) after platinum-based chemotherapy for clinical stage IIa-III NSGCT was performed unilaterally as well as bilaterally by two surgeons. Patients with retroperitoneal residual tumor > 1 cm and normalization of tumor markers after chemotherapy were included. Bilateral L-RPLND was performed with complete contralateral nerve sparing while the decision for ipsilateral nerve preservation was based on the volume of the residual mass in the respective standard field. The L-RPLND was completed in all patients without conversion. Median operation time was 248 min (range 95-397 min) and mean hospitalization time was 5 days (range 3-14 days). Furthermore, there was no difference in recurrence rate of the disease (p=0.45) between patients with unilateral or bilateral dissection. The postoperative ejaculatory function was normal in 37 out of 39 patients. The median follow-up period was 18.5 months (range 3-38 months) and 3 out of 39 patients developed recurrence (7.69 %). Post-chemotherapy L-RPLND is feasible with a lower complication rate and an adequate oncological safety and functional outcome. Due to the complexity of L-RPLND the procedure remains limited to institutions with extensive laparoscopic experience.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 50 条
  • [1] Post-chemotherapy nerve-sparing laparoscopic retroperitoneal lymph node dissection in stage IIB testicular cancer
    Kimura, Yasunori
    Nakamura, Terukazu
    Kawauchi, Akihiro
    Kawabata, Gaku
    Hongo, Fumiya
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (08) : 837 - 841
  • [2] Post-chemotherapy modified template retroperitoneal lymph node dissection in patients with nonseminomatous germ cell tumours
    Zor, Murat
    Yilmaz, Sercan
    Topuz, Bahadir
    Kaya, Engin
    Yalcin, Serdar
    Coguplugil, Adem Emrah
    Ince, Mehmet Emin
    Gurdal, Mesut
    AKTUELLE UROLOGIE, 2022, 53 (04) : 325 - 330
  • [3] Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma
    Sharma, Pranav
    Sverrisson, Einar F.
    Zargar-Shoshtari, Kamran
    Fishman, Mayer N.
    Sexton, Wade J.
    Dickinson, Shohreh I.
    Spiess, Philippe E.
    Poch, Michael A.
    Gilbert, Scott M.
    Pow-Sang, Julio M.
    CANADIAN JOURNAL OF UROLOGY, 2015, 22 (04) : 7882 - 7889
  • [4] Clinical outcome of post-chemotherapy retroperitoneal lymph node dissection in metastatic nonseminomatous germ cell tumour: A systematic review
    Haarsma, Rianne
    Blok, Joost M.
    van Putten, Kim
    Meijer, Richard P.
    EJSO, 2020, 46 (06): : 999 - 1005
  • [5] Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer
    Stephenson, Andrew J.
    Tal, Raanan
    Sheinfeld, Joel
    JOURNAL OF UROLOGY, 2006, 176 (05) : 1996 - 1999
  • [6] Post-chemotherapy Laparoscopic Retroperitoneal Lymph Node Dissection for Mixed Malignant Germ Cell Testicular Tumors
    Pickersgill, Nicholas A.
    Raval, Neel S.
    Kim, Eric H.
    Black, River G.
    Du, Kefu
    Figenshau, R. Sherburne
    CLINICAL GENITOURINARY CANCER, 2021, 19 (03) : 273.e1 - 273.e5
  • [7] External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer
    Vallier, Cedric
    Savoie, Pierre-Henri
    Delpero, Jean-Robert
    Bladou, Franck
    Gravis, Gwenaelle
    Salem, Naji
    Rossi, Dominique
    Walz, Jochen
    WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1573 - 1578
  • [8] Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer
    Subramanian, Vairavan S.
    Nguyen, Carvell T.
    Stephenson, Andrew J.
    Klein, Eric A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (05) : 504 - 509
  • [9] Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals
    Blok, Joost M.
    Meijer, Richard P.
    van der Poel, Henk G.
    Bex, Axel
    van Vooren, Jeanette
    van Urk, Japke J.
    Horenblas, Simon
    Bosch, J. L. H. Ruud
    WORLD JOURNAL OF UROLOGY, 2021, 39 (03) : 839 - 846
  • [10] Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors
    Nakamura, Terukazu
    Kawauchi, Akihiro
    Oishi, Masakatsu
    Ueda, Takashi
    Shiraishi, Takumi
    Nakanishi, Hiroyuki
    Kamoi, Kazumi
    Naya, Yoshio
    Hongo, Fumiya
    Okihara, Koji
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 791 - 795